Liposomal bupivacaine for Opioid Use, Unspecified
This study is evaluating whether a mixture of liposomal and standard bupivacaine is more effective than saline for pain relief in patients undergoing cardiac surgery.
See full descriptionAbout the trial for Opioid Use, Unspecified
Treatment Groups
This trial involves 2 different treatments. Liposomal Bupivacaine is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 4 and have been shown to be safe and effective in humans.
About The Treatment
Eligibility
This trial is for patients born any sex aged 18 and older. There are 4 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Liposomal bupivacaine will improve 1 primary outcome and 11 secondary outcomes in patients with Opioid Use, Unspecified. Measurement will happen over the course of up to 7 days.
Patient Q & A Section
What causes opioid use, unspecified?
Chronic pain, psychosocial factors and psychiatric disorders are associated with opioid use, but they do not completely account for it. Some of the factors that influence the use of opioids may also contribute to opioid dependence. There are several possible reasons why opioid use leads to opioid dependence, but the exact mechanisms are not clear. These may include misuse of prescription or recreational opioids or a combination of factors and the problem of addiction. The reasons for initiating opioid use and its influence on people in their middle to late forties are unknown. The factors contributing to relapse may be different in people with and without opioid dependence.
How many people get opioid use, unspecified a year in the United States?
The number of US adults prescribed opioid analgesics in 2007 (around 1.4 million) was greater than or equal to the number prescribed in the mid-1980s (around 1 million), the mid-1990s (around 2.1 million), 2000 (around 2.3 million), and 2007 (around 2.5 million).
What are the signs of opioid use, unspecified?
Data from a recent study provides evidence of many signs of opioid use. These signs may be helpful in determining treatment options and preventing addiction.
Can opioid use, unspecified be cured?
The evidence for the use of opioids for pain is weak, because it was only based on non-randomised, rather than randomised, studies. It is therefore not known whether the use of opioids, unspecified can be cured. A randomized controlled study is needed to determine whether opioid therapy is an effective treatment for long-lasting pain or for other indications.
What is opioid use, unspecified?
Although opioid use, unspecified is a common indicator for opioid drug use, the presence of an opioid-using indication may be more important for this variable than the presence of a heroin-using indication.
What are common treatments for opioid use, unspecified?
Chronic Opioid users typically have moderate-severe pain. Almost half had a history of prior pain treatment. The most common opioids in chronic opioid users were long-acting methadone (15%), oral tramadol (12%), methadone/Tramadol (10%), and heroin (5%). Methadone and oral tramadol were equally frequently used in acute opioid users. The most useful opioids in chronic opioid users were methadone (30%), oral tramadol (28%), oral buprenorphine (19%), oral pentazocine (13%), and buprenorphine/pentazocine (13%).
Does opioid use, unspecified run in families?
Results from a recent paper of this study were most consistent with a multifactorial model; familial determinants were important, but the environmental risk factors were not. There is an urgent need for a systematic systematic family history of the disorder in those who are referred for opiate abuse treatment.
What is the average age someone gets opioid use, unspecified?
While there was a predominance of men with age < 51 years, the sample was more representative of men aged between 51-58 years, as the majority of respondents were in that age bracket, with the average for the overall sample. The majority of respondents reported use in the previous 90 days, and over half reported a history of opioid use for any reason. Many respondents reported some combination of illicit drug use and opiate use in the past 3 months. Given opioid overdose deaths from the United States has increased 10-fold since the 1990s, the number of reports that were made of opioid use, as well as those that reported illicit drug use in a 12-month period, are of concern.
Is liposomal bupivacaine typically used in combination with any other treatments?
The use of liposomal bupivacaine is not limited to use in combination with other treatments alone. It is a treatment of its own which, as of July 2016, had received U.S. Food and Drug Administration (FDA) approval.
What are the latest developments in liposomal bupivacaine for therapeutic use?
The availability of liposomal formulation has brought about the introduction of new drug delivery systems into the market. A significant increase in the therapeutic efficiency of the drug is achieved by utilising the lipophilic property of liposomes to enhance the permeability of the drug across the blood-brain barrier (BBB) (Chaudhary, CMC Pharmaceuticals, 2011; Das, Advances in Ocular Pharmacology.
What does liposomal bupivacaine usually treat?
The current literature is weak in evidence. Lidocaine/metracaine and levobupivacaine can be used in combination with morphine in perioperative epidural analgesia. However, since there is very limited observational evidence, which supports the use of liposomal bupivacaine, further randomised controlled trials are warranted.
What is the latest research for opioid use, unspecified?
Patients must be aware of the possibility for overdose as one of the adverse side effects of opioid use, and must also contemplate the possibility of a substance-induced depression if they notice significant mood changes. There is a shortage of evidence for more stringent regulations to deal with opioid safety, especially when the public is not being informed about the risk of prescription medication misuse and overdose. It is important to identify the current guidelines and laws to protect users of prescription opioids from risks, by obtaining more valid and peer-reviewed data.